日本为2024/2025年免疫方案核准了最新现代COVID-19疫苗,以变体JN.1为目标。 Japan approved an updated Moderna COVID-19 vaccine targeting variant JN.1 for the 2024/2025 immunization program.

日本根据日本卫生部小组5月关于更新2024/2025年国家免疫方案疫苗的建议,批准了更新的现代COVID-19疫苗,目标是SARS-COV-2变体JN.1。 Japan has approved an updated COVID-19 vaccine from Moderna targeting the SARS-CoV-2 variant JN.1, following a recommendation from a Japanese health ministry panel in May to update vaccines for the 2024/2025 national immunization program. 更新的疫苗旨在更好地防止循环菌株,今后可以与季节性流感疫苗同时使用。 The updated vaccine aims to better protect against circulating strains and could be administered alongside seasonal flu vaccines in the future. 这项批准支持日本的国家免疫方案,该方案向65岁及65岁以上的人以及60至64岁的合格人提供疫苗接种。 The approval supports Japan's National Immunization Program, which offers vaccinations to individuals aged 65 and older, as well as qualifying individuals aged 60 to 64.